Left atrial appendage occlusion for stroke despite oral anticoagulation (resistant stroke). Results from the Amplatzer Cardiac Plug registry
Rev Esp Cardiol (Engl Ed). 2020 Jan;73(1):28-34.
doi: 10.1016/j.rec.2019.02.013.
Epub 2019 Apr 27.
[Article in
English,
Spanish]
Authors
Ignacio Cruz-González
1
, Rocío González-Ferreiro
2
, Xavier Freixa
3
, Sameer Gafoor
4
, Samera Shakir
5
, Heyder Omran
6
, Sergio Berti
7
, Gennaro Santoro
8
, Joelle Kefer
9
, Ulf Landmesser
10
, Jens Erik Nielsen-Kudsk
11
, Prapa Kanagaratnam
12
, Fabian Nietlispach
13
, Steffen Gloekler
5
, Adel Aminian
14
, Paolo Danna
15
, Marco Rezzaghi
7
, Friederike Stock
6
, Miroslava Stolcova
8
, Luis Paiva
16
, Marco Costa
16
, Xavier Millán
17
, Reda Ibrahim
18
, Tobias Tichelbäcker
19
, Wolfgang Schillinger
19
, Jai-Wun Park
20
, Horst Sievert
4
, Bernhard Meier
5
, Apostolos Tzikas
21
Affiliations
- 1 Servicio de Cardiología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), CIBERCV, Salamanca, Spain. Electronic address: [email protected].
- 2 Servicio de Cardiología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), CIBERCV, Salamanca, Spain.
- 3 Servicio de Cardiologia, Hospital Clínico, Universidad de Barcelona, Barcelona, Spain.
- 4 Department of Cardiology, CardioVascular Center Frankfurt, Frankfurt, Germany.
- 5 Department of Cardiology, University Hospital of Bern, Bern, Switzerland.
- 6 Department of Cardiology, University Hospital of Bonn, Bonn, Germany.
- 7 Department of Cardiology, Fondazione Toscana Gabriele Monasterio, Massa, Italy.
- 8 Department of Cardiology, Ospedale Careggi di Firenze, Florence, Italy.
- 9 Department of Cardiology, St-Luc University Hospital, Brussels, Belgium.
- 10 Department of Cardiology, University Hospital of Zurich, Zurich, Switzerland.
- 11 Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.
- 12 Department of Cardiology, Imperial College Healthcare NHS Trust, London, United Kingdom.
- 13 Department of Cardiology, University Hospital of Bern, Bern, Switzerland; Department of Cardiology, University Hospital of Zurich, Zurich, Switzerland.
- 14 Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium.
- 15 Department of Cardiology Ospedale Luigi Sacco, Milan, Italy.
- 16 Department of Cardiology, Coimbra University Hospital Centre, Coimbra, Portugal.
- 17 Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- 18 Department of Cardiology, Montreal Heart Institute, Montreal, Canada.
- 19 Department of Cardiology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Heart Center Cologne, Cologne, Germany.
- 20 Department of Cardiology, Coburg Hospital, Coburg, Germany.
- 21 Department of Cardiology, AHEPA University Hospital, Thessaloniki, Greece.
Abstract
Introduction and objectives:
Despite the efficacy of oral anticoagulant (OAC) therapy, some patients continue to have a high residual risk and develop a stroke on OAC therapy (resistant stroke [RS]), and there is a lack of evidence on the management of these patients. The aim of this study was to analyze the safety and efficacy of left atrial appendage occlusion (LAAO) as secondary prevention in patients with nonvalvular atrial fibrillation who have experienced a stroke/transient ischemic attack despite OAC treatment.
Methods:
We analyzed data from the Amplatzer Cardiac Plug multicenter registry on 1047 consecutive patients with nonvalvular atrial fibrillation undergoing LAAO. Patientes with previous stroke on OAC therapy as indication for LAAO were identified and compared with patients with other indications.
Results:
A total of 115 patients (11%) with RS were identified. The CHA2DS2-VASc and the HAS-BLED score were significantly higher in the RS group (respectively 5.5±1.5 vs 4.3±1.6; P <.001; 3.9±1.3 vs 3.1±1.2; P <.001). No significant differences were observed in periprocedural major safety events (7.8 vs 4.5%; P=.1). With a mean clinical follow-up of 16.2±12.2 months, the observed annual stroke/transient ischemic attack rate for the RS group was 2.6% (65% risk reduction) and the observed annual major bleeding rate was 0% (100% risk reduction).
Conclusions:
Patients with RS undergoing LAAO showed similar safety outcomes to patients without RS, with a significant reduction in stroke/transient ischemic attack and major bleeding events during follow-up. Adequately powered controlled trials are needed to further investigate the use of LAAO in RS patients.
Keywords:
Anticoagulación oral crónica; Anticoagulant therapy; Atrial fibrillation; Cierre percutáneo de la orejuela izquierda; Fibrilación auricular; Ictus isquémico; Ischemic stroke; Left atrial appendage occlusion.
Copyright © 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Administration, Oral
-
Aged
-
Anticoagulants / administration & dosage*
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / therapy*
-
Cardiac Catheterization / methods
-
Europe / epidemiology
-
Female
-
Follow-Up Studies
-
Humans
-
Incidence
-
Male
-
Registries*
-
Retrospective Studies
-
Septal Occluder Device*
-
Stroke / epidemiology
-
Stroke / etiology
-
Stroke / prevention & control*
-
Time Factors
-
Treatment Outcome